Immunotherapy in complex treatment of acute optic neuritis associated with herpesvirus infection

2021 ◽  
pp. 339-343
Author(s):  
D.А. Povalyaeva ◽  
◽  
V.V. Egorov ◽  
G.P. Smoliakova ◽  
L.P. Danilova ◽  
...  
Keyword(s):  
Optic Neuritis ◽  
Irrigation System ◽  
Functional Results ◽  
Complex Treatment ◽  
Herpesvirus Infection ◽  
Results Of Treatment ◽  
Acute Optic Neuritis ◽  
Key Words Optic Neuritis ◽  
Retrobulbar Space

Purpose. Evaluation clinical efficacy of complex treatment of optic neuritis (ON) associated with herpesvirus infection (HVI), including methods of immunotherapy. Material and methods. The clinical study involved 26 people (26 eyes) with acute ON associated with HVI. The treatment regimen for all patients within 10 days included delivery through irrigation system implanted into the retrobulbar space to optic nerve: solutions Dexamethasone on decreasing scheme, Emoxypine 1% 0.5 ml and Dicynone 12.5% 0.5 ml. All patients were divided into 2 groups depending on characteristics of therapy. The 1st group consisted of 12 patients, who were treated according to the standard method. 2nd group consisted of 14 patients who received additional intramuscular Imunofan. The duration of immunotherapy was 10–12 days. Results. Analysis of obtained datas showed that more significant positive dynamics was noted in the clinical course of ON in patients of the 2nd group of observation in comparison with the 1st group. Conclusion. The developed strategy of etiotropic and pathogenetic immunotherapy at ON associated with HVI infection, allows shortening recovery time and improving functional results of treatment in absence of relapses of disease within 1 year of follow-up. Key words: optic neuritis, herpesvirus infection, corticosteroid therapy, immunotherapy.

Evaluation clinical efficacy of immunotherapy in complex treatment of acute optic neuritis associated with herpesvirus infection

2021 ◽  
pp. 167-171
Author(s):  
D.А. Povalyaeva ◽  
◽  
V.V. Egorov ◽  
G.P. Smoliakova ◽  
L.P. Danilova ◽  
...  
Keyword(s):  
Optic Neuritis ◽  
Clinical Efficacy ◽  
Irrigation System ◽  
Functional Results ◽  
Complex Treatment ◽  
Herpesvirus Infection ◽  
Results Of Treatment ◽  
Acute Optic Neuritis ◽  
Key Words Optic Neuritis ◽  
Retrobulbar Space

Purpose. To study the clinical efficacy of complex treatment of optic neuritis (ON) associated with herpesvirus infection (HVI), including methods of immunotherapy. Material and methods. The clinical study involved 37 people (37 eyes) with acute ON associated with HVI. The treatment regimen for all patients within 10 days included delivery through irrigation system implanted into the retrobulbar space to optic nerve: solutions Dexamethasone on decreasing scheme, Emoxypine 1% 0.5 ml and Dicynone 12.5% 0.5 ml, in combination with administration of drugs neuroprotection. All patients were divided into 2 groups depending on characteristics of therapy. The 1st group consisted of 17 patients, who were treated according to the standard method. 2nd group consisted of 20 patients who received additional intramuscular Imunofan in the regimen and doses according to the manufacturer's instructions. Results. Analysis of obtained datas showed that more significant positive dynamics was noted in the clinical course of ON in patients of the 2nd group of observation in comparison with the 1st group. Conclusion. The strategy of etiotropic and pathogenetic immunotherapy at ON, associated with HVI infection, developed by us, allows to shorten recovery time and improve functional results of treatment in absence of relapses of disease within 1 year of follow-up. Key words: optic neuritis, herpesvirus infection, corticosteroid therapy, immunotherapy.

In Reply to Vitiello et al.: Acute Optic Neuritis Diagnosed by Bedside Ultrasound in an Emergency Department: Follow-Up and Clarification

2020 ◽  
Vol 59 (3) ◽  
pp. 449-451
Author(s):  
Mark Philip Saigh ◽  
Harold Martin Plauché ◽  
Christine Butts ◽  
Amer Karam Karam ◽  
Salvador J. Suau ◽  
...  
Keyword(s):  
Emergency Department ◽  
Optic Neuritis ◽  
Bedside Ultrasound ◽  
Acute Optic Neuritis

P14.53 Immunotherapy in the complex treatment of HGG

2021 ◽  
Vol 23 (Supplement_2) ◽  
pp. ii47-ii48
Author(s):  
A Rynda ◽  
V Olyushin ◽  
D Rostovtsev
Keyword(s):  
Malignant Gliomas ◽  
Long Term Results ◽  
Complex Treatment ◽  
Average Life ◽  
Average Life Expectancy ◽  
Standard Methods ◽  
Results Of Treatment ◽  
Antitumor Immunotherapy

Abstract BACKGROUND To improve the long-term results of complex treatment of patients with malignant gliomas MATERIAL AND METHODS The long-term results of treatment of 220 patients with malignant gliomas of supratentorial localization (anaplastic astrocytomas, glioblastomas, giant cell glioblastomas, gliosarcomas) were evaluated. Of these patients, in addition to standard treatment methods (surgery, radiation therapy and chemotherapy), 110 patients underwent specific antitumor immunotherapy. In 110 patients, only standard methods were used in the complex treatment structure. Follow-up results were considered follow-up data, and a relapse-free period was also evaluated. RESULTS The implementation of specific antitumor immunotherapy in patients with malignant gliomas was safe and did not lead to an increase in the number of complications compared with the control group. It was revealed that the use of immunotherapy based on autologous dendritic cells, in addition to standard methods of treating patients, increases the average life expectancy (in patients with anaplastic astrocytomas up to 40.5 months (p = 0.001), in patients with glioblastomas up to 21.8 months (p = 0.002)) and the value of the relapse-free period (in patients with anaplastic astrocytomas up to 17.4 months (p = 0.002), in patients with glioblastomas up to 14.3 months (p = 0.003)), provided that three or more courses are carried out. Conducting 1 or 2 courses of immunotherapy does not significantly affect the average life expectancy and median survival of patients. CONCLUSION The development and use in clinical practice of specific antitumor immunotherapy based on autologous dendritic cells seems to be a very promising direction for further research, the development of which will improve the long-term results of treatment of patients.

scholarly journals Optic neuritis of MOG-IgG-associated autoimmune disorders: a case report

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Tiantian Li ◽  
Jian Zhou ◽  
Xiaoling Yan ◽  
Ran Duan ◽  
Xiaobo Zhu
Keyword(s):  
Optic Neuritis ◽  
Steroid Therapy ◽  
Case Presentation ◽  
Acute Optic Neuritis ◽  
Long Term Follow Up ◽  
Lower Titer ◽  
T2 Hyperintensity ◽  
Demyelinating Disorders

Abstract Background The diagnosis of immunoglobulin G serum antibodies to myelin oligodendrocyte glycoprotein (MOG-IgG) associated inflammatory demyelinating disorders can be confirmed by the presence of MOG-IgG, yet its general cut-off concentration had not yet to be defined. Whether it is significant that a seropositive lower titer level for MOG-IgG could cause disease is still unknown. Case presentation A 55-year-old Chinese woman presented with acute optic neuritis manifestations in the left eye. MRI showed a left optic nerve demyelination image and a T2 hyperintensity at C7 vertebral segment without any extra specific lesions. AQP4-IgG was tested seronegative, while the MOG-IgG was positive, titer 1:10, by indirect immunofluorescence. Considering the lower concentration, we retested serum MOG-IgG after 6 months of steroid therapy, using cell-based assay, then we still got the same result which was also barely above the negative cut-off value. So, the clinical diagnose was “possible MOG-IgG-associated encephalomyelitis”. The woman’s condition improved by steroid therapy without relapse. Conclusions Seropositive MOG-IgG, even at a lower level, could lead to an autoimmune inflammatory demyelination. In adults, it commonly presents as ON and myelitis. Although the patient had a considerable reaction, steroid therapy could not make MOG-IgG seronegative, instead, the antibody may persist even during remission and flare-ups can recur after steroid withdrawal. Therefore, a long-term follow-up is necessary to monitor the patient’s prognosis.

scholarly journals Botox’s Place in the Complex Treatment of Oculomotor System Pathology (the Optimal “Portrait” of the Patient for the Chemodenervation)

2018 ◽  
Vol 15 (2S) ◽  
pp. 261-267
Author(s):  
I. L. Plisov ◽  
V. V. Cherhykh ◽  
V. V. Atamanov ◽  
N. G. Antsiferova ◽  
V. B. Pushchina ◽  
...  
Keyword(s):  
Optimal Algorithm ◽  
Cranial Nerves ◽  
Optimal Dose ◽  
Functional Results ◽  
Oculomotor System ◽  
Extraocular Muscles ◽  
Alternative Methods ◽  
Complex Treatment ◽  
Patients Âgés ◽  
Results Of Treatment

Introduction. To summarize our fifteen-years clinical experience of using Botox in strabismology and determine the indications for the most effective use of chemodenervation in the complex treatment of oculomotor system pathology.Patients and methods. To carry out chemodenervation of extraocular muscles, Botox was used. The optimal dose of Botox for intramuscular injection ranged from 1.25 to 5.0 units. The choice of dosage depends on the patient’s age, the type oculomotor system pathology, the level of muscular dysfunction and the purpose of the treatment. The treatment was performed in 376 patients with various disorders of oculomotor system. At the time of treatment, the patients’ ages ranged from 12 to 78 years. Injection of Botox into the extraocular muscles in all cases was the primary method of treatment.Results. In general, the state of relative functional recovery was achieved in 71.81% of cases (in 270 patients). The best results were obtained in treatment of decompensated heterophories, acute heterotrophies, atypical heterotrophies and primary hyperfunction of the inferior oblique muscles (in 100% of cases). In these conditions, the binocular vision was preserved in patients, and the imbalance of the oculomotor system did not show any sign of incomitance. However, patients with paralysis and paresis of the cranial nerves chemodenervation allowed creating conditions for a more complete restoration of muscular functions, to avoid the occurrence of a secondary imbalance in the oculomotor system. In 70.3% cases (185 patients), subsequent surgical treatment was not required. Reliable functional results of treatment allowed creating the optimal algorithm for chemodenervation.Discussion. Chemodenervation of extraocular muscles is an effective independent and additional method of complex treatment of oculomotor system pathology and expands opportunities in patients’ rehabilitation. To achieve maximum functional results, it is necessary to select patients correctly for this procedure, taking into account its appropriateness and advantages over alternative methods of treatment, selection of optimal dosages of Botox. 

Sign in / Sign up

Export Citation Format

Share Document